Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

Status Completed

Clinical Trial Summary

This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).

Clinical Trial Description

Post-traumatic stress disorder (PTSD) is a chronic and common anxiety disorder that follows exposure to an overwhelming traumatic event. The majority of patients with PTSD also meet criteria for other psychiatric disorders and PTSD is associated with an increased risk for suicide attempts.

PTSD is responsive to psychological and pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), but response rates rarely exceed 60%, and even fewer patients (20-30%) achieve clinical remission. Thus, there is a clear need to develop novel and improved therapeutics for PTSD.

The study is divided into 4 phases:

Phase 1 (Screening): a 1 week no drug screening period to assess study eligibility.

Phase 2 (Pre-Treatment Testing Period): Eligible patients will be enrolled into a 1 week Testing Phase, which will include neuropsychological and neurophysiological testing as well as blood draws and electrocardiogram.

Phase 3 (Treatment Period): Eligible patients will be enrolled in a two-armed 6-week period of double-blind placebo-controlled acute treatment. All subjects who continue to meet eligibility criteria will be randomized to one of two groups: GSK561679 (at a fixed dose of 350 mg/day) or placebo. Randomization will be performed at a 1:1 ratio into two treatment groups. Neuropsychological and neurophysiological testing will be repeated after 5 weeks of the double-blind treatment period.

Phase 4 (Follow-up Period): Safety follow-up visits will be conducted 1 week and 1 month after the end of the treatment Phase 3. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01018992
Study type	Interventional
Source	Emory University
Contact
Status	Completed
Phase	Phase 2
Start date	December 2009
Completion date	August 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05620381` - Health and Sleep Assessment After the Strasbourg Attacks of December 11, 2018
Completed	`NCT02856412` - Improving Mind/Body Health and Functioning With Integrative Exercise	N/A
Recruiting	`NCT05400200` - PTSD and Self-regulation: Coping, Emotional Regulation and Cognitive Control and Their Relationships to Symptom Management	N/A
Not yet recruiting	`NCT06088303` - Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication	N/A
Not yet recruiting	`NCT03652922` - Propranolol Reactivation Mismatch (PRM) Treatment for PTSD	Phase 4
Completed	`NCT02875912` - Prospective Evaluation of Family Care Rituals in the ICU	N/A
Completed	`NCT01589575` - Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives	N/A
Completed	`NCT01291368` - Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care	N/A
Completed	`NCT00990106` - Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)	N/A
Active, not recruiting	`NCT00657787` - Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans
Completed	`NCT00880152` - Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study	N/A
Completed	`NCT00835627` - Treatment Trial for Psychogenic Nonepileptic Seizures	Phase 4
Completed	`NCT01365247` - Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT00514956` - Effect of Emotional Freedom Technique and Diaphragmatic Breathing on Post Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT00419029` - Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment	N/A
Completed	`NCT00333710` - Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD	N/A
Completed	`NCT01120847` - Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition
Completed	`NCT00069225` - Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder	N/A
Completed	`NCT00055354` - Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT00186212` - Alternative Support for Rural and Isolated Women in an HMO	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.